Biotech Values

[vinmantoo]

I agree the odds of an antiviral showing success in patients with long covid is fairly low, however there is still a narrative for upselling a protease inhibitor related to long covid. Lowering the risk of long covid in those with acute infection. There is data that paxlovid does this to some degree, and the next most advanced PI from Shionogi is looking at this as an endpoint. It's possible use may broaden for the drug if there is firm proof that you can lower the risk of acquiring long covid

The point is that scientists and medical experts in the field are seriously considering and investigating the idea that viral reservoirs may be a cause of long Covid, at least for some people. Obviously this has to be tested using anti-viral drugs. Paxlovid may not be the best drug as other drugs with better tissue distribution and higher may be better, such as EDP-235. My other point is that someone with zero training or knowledge has summarily dismissed the possible role that viral reservoirs may have in long Covid. That speaks volumes, none of it good.

Trace amounts of virus in blood stool etc could be indicative of significant viral loads in other compartments like CNS. Neurosyphilis is an example where you can barely detect anything in blood but you often can in CNS, and antibiotics are still recommended to clear this reservoir.

Interesting information about the CNS for bacterial infections. However, we don't know which compartments Covid may be hiding in or which contribute to long Covid, if any. Time, drug testing and further research will tell.